Product Description
Mechanisms of Action: DRI Inhibitor,NRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Canada | Chile | Dominican Republic | Ecuador | Ireland | Korea | Mexico | New Zealand | Peru | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: NLS Pharmaceutics
Company Location: STANS V8 CH-6370
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Cataplexy|Narcolepsy
Phase 2: Disorders of Excessive Somnolence